KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Common Equity: 2018-2025

Historic Common Equity for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -$451.4 million.

  • Esperion Therapeutics' Common Equity fell 21.92% to -$451.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$451.4 million, marking a year-over-year decrease of 21.92%. This contributed to the annual value of -$388.7 million for FY2024, which is 14.57% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Common Equity of -$451.4 million as of Q3 2025, which was down 4.12% from -$433.5 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Common Equity peaked at -$196.9 million during Q4 2021, and registered a low of -$455.0 million during Q4 2023.
  • Over the past 3 years, Esperion Therapeutics' median Common Equity value was -$388.7 million (recorded in 2024), while the average stood at -$388.7 million.
  • In the last 5 years, Esperion Therapeutics' Common Equity plummeted by 4,148.05% in 2021 and then increased by 18.91% in 2022.
  • Esperion Therapeutics' Common Equity (Quarterly) stood at -$196.9 million in 2021, then plummeted by 64.40% to -$323.8 million in 2022, then crashed by 40.53% to -$455.0 million in 2023, then climbed by 14.57% to -$388.7 million in 2024, then dropped by 21.92% to -$451.4 million in 2025.
  • Its Common Equity stands at -$451.4 million for Q3 2025, versus -$433.5 million for Q2 2025 and -$426.2 million for Q1 2025.